Embolic strokes of undetermined source represent 20% of ischemic strokes and are associated with a high rate of recurrence. Anticoagulant treatment with rivaroxaban, an oral factor Xa inhibitor, ma ...

Anticoagulation Uncertainty in Embolic Stroke of Undetermined Source. Patrice Wendling. September 20, 2024 . 0. 0.

After an initial embolic stroke of undetermined source, or ESUS, the most prevalent recurrent infarct was another ESUS, according to an analysis of the NAVIGATE-ESUS trial.Researchers also noted ...

The phase III NAVIGATE ESUS trial comparing rivaroxaban and low-dose aspirin in patients with a recent embolic stroke of undetermined source was halted prematurely after an interim analysis ...

Tao L, Li X-Q, Hou X-W, et al. Intracranial atherosclerotic plaque as a potential cause of embolic stroke of undetermined source. J Am Coll Cardiol. 2021;77:680-691. Hart RG, Perera KS. Intracranial ...

In patients with embolic stroke of undetermined source, atrial fibrosis predicted recurrent stroke or new atrial fibrillation, according to data presented at the virtual Heart Rhythm Society ...

Large, international trials comparing new, direct oral anticoagulants and aspirin in patients with embolic stroke of undetermined source have recently been launched (NCT02239120, NCT02313909, and ...

Patients with embolic stroke of undetermined source and left ventricular dysfunction may benefit from anticoagulation to prevent a further stroke, a new analysis of the NAVIGATE ESUS trial suggested.

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in ...

Embolic stroke of undetermined source is caused by a blood clot, and affects approximately 300,000 people each year in North America and Europe / Phase III NAVIGATE ESUS study will investigate ...